Altimmune (ALT) options active on wide price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall St ends higher on chip stocks recovery; earnings in focus
- Oil prices rise to five-week high on US-Iran attacks, Houthi blockade threat
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
- Myriad Genetics launches four-in-one prenatal genetic screen
Altimmune (ALT) Prices 3.37M Share Common Offering at $23/Sh
July 14, 2020 5:45 AM EDTAltimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,369,564 shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase 1,630,436 shares of its common stock at an exercise price of $0.0001 per share. The public offering price of each share of common stock is $23.00 and the public offering price of each pre-funded warrant is $22.999 per underlying share. In addition, Altimmune has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the... More
